A novel method for engineering autologous non-thrombogenic in situ tissue-engineered blood vessels for arteriovenous grafting

Journal article (2020)

Authors

W. J. Geelhoed Leiden University Medical Center, Einthoven Laboratory of Vascular and Regenerative Medicine
F. F.R. Damanik Universiteit Maastricht
Jaap Hamming Leiden University Medical Center
M. S. van Agen Leiden University Medical Center, Einthoven Laboratory of Vascular and Regenerative Medicine
H. C. de Boer Leiden University Medical Center, Einthoven Laboratory of Vascular and Regenerative Medicine
M. Tobón Restrepo Universiteit Utrecht
A. Kislaya Fluid Mechanics - Mechanical, Maritime and Materials Engineering
C. Poelma Multi Phase Systems - Mechanical, Maritime and Materials Engineering
A. J. van Zonneveld Einthoven Laboratory of Vascular and Regenerative Medicine, Leiden University Medical Center
More Authors... External organisation
Research Group
Fluid Mechanics (Mechanical, Maritime and Materials Engineering) (TU Delft)
Copyright: © 2020 W. J. Geelhoed, F. F.R. Damanik, J. F. Hamming, M. S. van Agen, H. C. de Boer, M. Tobón Restrepo, A. Kislaya, C. Poelma, A. J. van Zonneveld, More Authors
DOI: https://doi.org/10.1016/j.biomaterials.2019.119577
More Info
expand_more

Published Date

2020

Language

English

Reuse Rights

Other than for strictly personal use, it is not permitted to download, forward or distribute the text or part of it, without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license such as Creative Commons.

Faculty

Mechanical, Maritime and Materials Engineering

Department

Process and Energy

Research Group

Fluid Mechanics

Abstract

The durability of prosthetic arteriovenous (AV) grafts for hemodialysis access is low, predominantly due to stenotic lesions in the venous outflow tract and infectious complications. Tissue engineered blood vessels (TEBVs) might offer a tailor-made autologous alternative for prosthetic grafts. We have designed a method in which TEBVs are grown in vivo, by utilizing the foreign body response to subcutaneously implanted polymeric rods in goats, resulting in the formation of an autologous fibrocellular tissue capsule (TC). One month after implantation, the polymeric rod is extracted, whereupon TCs (length 6 cm, diameter 6.8 mm) were grafted as arteriovenous conduit between the carotid artery and jugular vein of the same goats. At time of grafting, the TCs were shown to have sufficient mechanical strength in terms of bursting pressure (2382 ± 129 mmHg), and suture retention strength (SRS: 1.97 ± 0.49 N). The AV grafts were harvested at 1 or 2 months after grafting. In an ex vivo whole blood perfusion system, the lumen of the vascular grafts was shown to be less thrombogenic compared to the initial TCs and ePTFE grafts. At 8 weeks after grafting, the entire graft was covered with an endothelial layer and abundant elastin expression was present throughout the graft. Patency at 1 and 2 months was comparable with ePTFE AV-grafts. In conclusion, we demonstrate the remodeling capacity of cellularized in vivo engineered TEBVs, and their potential as autologous alternative for prosthetic vascular grafts.

Files

1_s2.0_S0142961219306763_main.... (pdf)
(pdf | 3.82 Mb)
- Embargo expired in 29-04-2020
Unknown license